GILEAD SCIENCES, INC. Research and Development Expense
GILEAD SCIENCES, INC. (GILD) reported Research and Development Expense of $1.10 billion for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-05-06
- GILEAD SCIENCES, INC. research and development expense for the quarter ending 2020-03-31 was $1.10B, a 4.16% increase year-over-year.
- GILEAD SCIENCES, INC. research and development expense for the quarter ending 2019-12-31 was $1.90B, a 2.62% decline year-over-year.
- GILEAD SCIENCES, INC. research and development expense for the quarter ending 2019-09-30 was $4.99B, a 431.42% increase year-over-year.
- GILEAD SCIENCES, INC. research and development expense for the quarter ending 2019-06-30 was $1.16B, a 2.68% decline year-over-year.
- GILEAD SCIENCES, INC. research and development expense for fiscal 2019 was $9.11B, a 81.47% increase from fiscal 2018.
- GILEAD SCIENCES, INC. research and development expense for fiscal 2018 was $5.02B, a 34.39% increase from fiscal 2017.
- GILEAD SCIENCES, INC. research and development expense for fiscal 2017 was $3.73B, a 26.76% decline from fiscal 2016.
- GILEAD SCIENCES, INC. research and development expense for fiscal 2016 was $5.10B, a 69.14% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $1.10B 10-Q · filed 2020-05-06 | $3.00B derived: sum of 2 quarters · filed 2020-05-06 | $7.99B derived: sum of 3 quarters · filed 2020-05-06 | $9.15B derived: sum of 4 quarters · filed 2020-05-06 | ||||
| 2019-12-31 | $1.90B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $6.89B derived: sum of 2 quarters · filed 2020-02-25 | $8.05B derived: sum of 3 quarters · filed 2020-02-25 | $9.11B 10-K · filed 2020-02-25 | ||||
| 2019-09-30 | $4.99B 10-Q · filed 2019-11-05 | $6.15B derived: sum of 2 quarters · filed 2019-11-05 | $7.21B 10-Q · filed 2019-11-05 | $9.16B derived: sum of 4 quarters · filed 2020-05-06 | ||||
| 2019-06-30 | $1.16B 10-Q · filed 2019-08-06 | $2.22B 10-Q · filed 2019-08-06 | $4.17B derived: sum of 3 quarters · filed 2020-05-06 | $5.11B derived: sum of 4 quarters · filed 2020-05-06 | ||||
| 2019-03-31 | $1.06B 10-Q · filed 2020-05-06 | $3.01B derived: sum of 2 quarters · filed 2020-05-06 | $3.95B derived: sum of 3 quarters · filed 2020-05-06 | $5.14B derived: sum of 4 quarters · filed 2020-05-06 | ||||
| 2018-12-31 | $1.95B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.89B derived: sum of 2 quarters · filed 2020-02-25 | $4.08B derived: sum of 3 quarters · filed 2020-02-25 | $5.02B 10-K · filed 2020-02-25 | ||||
| 2018-09-30 | $939.00M 10-Q · filed 2019-11-05 | $2.13B derived: sum of 2 quarters · filed 2019-11-05 | $3.07B 10-Q · filed 2019-11-05 | $4.22B derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $1.19B 10-Q · filed 2019-08-06 | $2.13B 10-Q · filed 2019-08-06 | $3.28B derived: sum of 3 quarters · filed 2020-02-25 | $4.07B derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $937.00M 10-Q · filed 2019-05-08 | $2.09B derived: sum of 2 quarters · filed 2020-02-25 | $2.88B derived: sum of 3 quarters · filed 2020-02-25 | $3.74B derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $1.15B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $1.94B derived: sum of 2 quarters · filed 2020-02-25 | $2.80B derived: sum of 3 quarters · filed 2020-02-25 | $3.73B 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $789.00M 10-Q · filed 2018-11-06 | $1.65B derived: sum of 2 quarters · filed 2018-11-06 | $2.58B 10-Q · filed 2018-11-06 | $3.79B derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | $864.00M 10-Q · filed 2018-08-06 | $1.79B 10-Q · filed 2018-08-06 | $3.00B derived: sum of 3 quarters · filed 2019-02-26 | $4.14B derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | $931.00M 10-Q · filed 2018-05-09 | $2.14B derived: sum of 2 quarters · filed 2019-02-26 | $3.28B derived: sum of 3 quarters · filed 2019-02-26 | $4.76B derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | $1.21B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $2.35B derived: sum of 2 quarters · filed 2019-02-26 | $3.83B derived: sum of 3 quarters · filed 2019-02-26 | $5.10B 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $1.14B 10-Q · filed 2017-11-07 | $2.63B derived: sum of 2 quarters · filed 2017-11-07 | $3.89B 10-Q · filed 2017-11-07 | $4.65B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $1.48B 10-Q · filed 2017-08-07 | $2.75B 10-Q · filed 2017-08-07 | $3.51B derived: sum of 3 quarters · filed 2018-02-27 | $4.25B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $1.26B 10-Q · filed 2017-05-10 | $2.02B derived: sum of 2 quarters · filed 2018-02-27 | $2.77B derived: sum of 3 quarters · filed 2018-02-27 | $3.58B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $757.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.50B derived: sum of 2 quarters · filed 2018-02-27 | $2.32B derived: sum of 3 quarters · filed 2018-02-27 | $3.01B 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $743.00M 10-Q · filed 2016-11-07 | $1.56B derived: sum of 2 quarters · filed 2016-11-07 | $2.26B 10-Q · filed 2016-11-07 | $3.30B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $818.00M 10-Q · filed 2016-08-05 | $1.51B 10-Q · filed 2016-08-05 | $2.56B derived: sum of 3 quarters · filed 2017-02-27 | $3.19B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $696.00M 10-Q · filed 2016-05-06 | $1.74B derived: sum of 2 quarters · filed 2017-02-27 | $2.37B derived: sum of 3 quarters · filed 2017-02-27 | $2.96B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $1.04B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.68B derived: sum of 2 quarters · filed 2017-02-27 | $2.26B derived: sum of 3 quarters · filed 2017-02-27 | $2.85B 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $630.00M 10-Q · filed 2015-11-04 | $630.47M 10-Q · filed 2014-11-05 | $1.21B derived: sum of 2 quarters · filed 2015-11-04 | $1.81B 10-Q · filed 2015-11-04 | $1.81B 10-Q · filed 2014-11-05 | $2.36B derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-30 | $584.00M 10-Q · filed 2015-08-05 | $583.92M 10-Q · filed 2014-08-04 | $1.18B 10-Q · filed 2015-08-05 | $1.18B 10-Q · filed 2014-08-04 | $1.73B derived: sum of 3 quarters · filed 2016-02-24 | $2.28B derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-31 | $595.00M 10-Q · filed 2015-05-08 | $594.98M 10-Q · filed 2014-05-07 | $1.15B derived: sum of 2 quarters · filed 2016-02-24 | $1.69B derived: sum of 3 quarters · filed 2016-02-24 | $2.22B derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $552.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $1.10B derived: sum of 2 quarters · filed 2016-02-24 | $1.62B derived: sum of 3 quarters · filed 2016-02-24 | $2.12B 10-K · filed 2016-02-24 | $2.12B 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $546.24M 10-Q · filed 2014-11-05 | $1.07B derived: sum of 2 quarters · filed 2014-11-05 | $1.57B 10-Q · filed 2014-11-05 | $2.01B derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | $523.90M 10-Q · filed 2014-08-04 | $1.02B 10-Q · filed 2014-08-04 | $1.46B derived: sum of 3 quarters · filed 2015-02-25 | $1.93B derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | $497.63M 10-Q · filed 2014-05-07 | $937.35M derived: sum of 2 quarters · filed 2015-02-25 | $1.40B derived: sum of 3 quarters · filed 2015-02-25 | $1.80B derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $439.71M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $905.54M derived: sum of 2 quarters · filed 2015-02-25 | $1.30B derived: sum of 3 quarters · filed 2015-02-25 | $1.76B 10-K · filed 2015-02-25 | $1.76B 10-K · filed 2014-02-25 | |||
| 2012-09-30 | $465.83M 10-Q · filed 2013-10-31 | $862.08M derived: sum of 2 quarters · filed 2013-10-31 | $1.32B 10-Q · filed 2013-10-31 | |||||
| 2012-06-30 | $396.24M 10-Q · filed 2013-08-01 | $854.46M 10-Q · filed 2013-08-01 | ||||||
| 2012-03-31 | $458.21M 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $1.23B 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |